Current Cancer Drug Targets
Volume 21, 11 Issues, 2021
ISSN: 1873-5576 (Online)
ISSN: 1568-0096 (Print)
This journal supports open access
ISSN: 1873-5576 (Online)
ISSN: 1568-0096 (Print)
This journal supports open access
Open Access Articles
The Roles of Alternative Splicing in Tumor-immune Cell Interactions
, 2020; 20(10): 729 - 740Yue Wang, Honglei Zhang*, Baowei Jiao*, Jianyun Nie*, Xiyin Li, Wenhuan Wang and Hairui Wang
Cancer Cell-derived Secretory Factors in Breast Cancer-associated Lung Metastasis: Their Mechanism and Future Prospects
, 2020; 20(3): 168 - 186Tabinda Urooj*, Bushra Wasim, Shamim Mushtaq, Syed Nudrat Nawaid Shah and Muzna Shah
Combinatorial Inhibition of mTORC2 and Hsp90 Leads to a Distinctly Effective Therapeutic Strategy in Malignant Pheochromocytoma
, 2019; 19(9): 698 - 706Xiaohua Zhang, Fengbin Gao and Shan Zhong*
Linc01638 Promotes Tumorigenesis in HER2+ Breast Cancer
, 2019; 19(1): 74 - 80Peng Liu, Hailin Tang, Jiali Wu, Xingsheng Qiu, Yanan Kong, Lijuan Zhang, Xinhua Xie* and Xiangsheng Xiao*
Role of MicroRNAs in Treatment Response in Prostate Cancer
, 2018; 18(10): 929 - 944Anshuli Razdan, Paul de Souza* and Tara Laurine Roberts
Noxa: Role in Cancer Pathogenesis and Treatment
, 2018; 18(10): 914 - 928Rami Z. Morsi, Rouba Hage-Sleiman, Hadile Kobeissy and Ghassan Dbaibo*
HR+, HER2– Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles
, 2017; 17(7): 637 - 649Sarah L. Sammons, Donna L. Topping and Kimberly L. Blackwell*
Advances in Synergistic Combinations of Chinese Herbal Medicine for the Treatment of Cancer
, 2016; 16(4): 346 - 356Xue-Qing Hu, Yang Sun, Eric Lau, Ming Zhao and Shi-Bing Su
A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast Cancer
, 2015; 15(8): 665 - 683Otília Menyhart, Libero Santarpia and Balazs Gyorffy
Cancer Stem Cells in Solid and Liquid Tissues of Breast Cancer Patients: Characterization and Therapeutic Perspectives
, 2015; 15(3): 256 - 269Rena Chiotaki, Hara Polioudaki and Panayiotis A. Theodoropoulos
Platycodin D Induces Tumor Growth Arrest by Activating FOXO3a Expression in Prostate Cancer in vitro and in vivo
, 2014; 14(9): 860 - 871Rui Zhou, Zongliang Lu, Kai Liu, Jing Guo, Jie Liu, Yong Zhou, Jian Yang, Mantian Mi and Hongxia Xu
Pleiotropic Role of HSF1 in Neoplastic Transformation
, 2014; 14(2): 144 - 155Natalia Vydra, Agnieszka Toma and Wieslawa Widlak
MicroRNAs as Critical Regulators Involved in Regulating Epithelial- Mesenchymal Transition
, 2013; 13(9): 935 - 944Xiaodi Zhao, Yuanyuan Lu, Yongzhan Nie and Daiming Fan
β-Catenin Knockdown in Liver Tumor Cells by a Cell Permeable Gamma Guanidine-based Peptide Nucleic Acid
, 2013; 13(8): 867 - 878Evan Delgado, Raman Bahal, Jing Yang, Jung M. Lee, Danith H Ly and Satdarshan P. S. Monga
Signal Transduction in Human Cutaneous Melanoma and Target Drugs
, 2013; 13(8): 843 - 866Anatoly B. Uzdensky, Svetlana V. Demyanenko and Mikhail Y. Bibov
Use of Single Nucleotide Polymorphism Array Technology to Improve the Identification of Chromosomal Lesions in Leukemia
, 2013; 13(7): 791 - 810Ilaria Iacobucci, Annalisa Lonetti, Cristina Papayannidis and Giovanni Martinelli
Autophagy in Chronic Myeloid Leukaemia: Stem Cell Survival and Implication in Therapy
, 2013; 13(7): 724 - 734Gudmundur V. Helgason, Arunima Mukhopadhyay, Maria Karvela, Paolo Salomoni, Bruno Calabretta and Tessa L. Holyoake
New Insights Into Biology of Chronic Myeloid Leukemia: Implications in Therapy
, 2013; 13(7): 711 - 723Michele Cea, Antonia Cagnetta, Alessio Nencioni, Marco Gobbi and Franco Patrone
Unmet Needs in Ovarian Cancer: Dividing Histologic Subtypes to Exploit Novel Targets and Pathways
, 2013; 13(6): 698 - 707Vijaya Galic, Robert L. Coleman and Thomas J. Herzog
Targeting Hypoxia for Sensitization of Tumors to Radio- and Chemotherapy
, 2013; 13(6): 670 - 685Khaled Ghattass, Rana Assah, Marwan El-Sabban and Hala Gali-Muhtasib
Anti-inflammatory Phytochemicals for Chemoprevention of Colon Cancer
, 2013; 13(5): 542 - 557Venkateshwar Madka and Chinthalapally V. Rao
miRNAs in Cancer Prevention and Treatment and as Molecular Targets for Natural Product Anticancer Agents
, 2013; 13(5): 519 - 541Biyun Qian, Subhasree A. Nag, Yuliang Su, Sukesh Voruganti, Jiang-Jiang Qin, Ruiwen Zhang and William C. S. Cho
VEGF in Tumor Progression and Targeted Therapy
, 2013; 13(4): 423 - 443Vladimir P. Chekhonin, Sergey A. Shein, Anna A. Korchagina and Olga I. Gurina
Nanomedicines as Cancer Therapeutics: Current Status
, 2013; 13(4): 362 - 378Sohail Akhter, Iqbal Ahmad, Mohammad Zaki Ahmad, Farshad Ramazani, Anjali Singh, Ziyaur Rahman, Farhan Jalees Ahmad, Gert Storm and Robbert J. Kok
P-glycoprotein Inhibition as a Therapeutic Approach for Overcoming Multidrug Resistance in Cancer: Current Status and Future Perspectives
, 2013; 13(3): 326 - 346Ziyad Binkhathlan and Afsaneh Lavasanifar
Targeting Tyrosine Kinase Receptors in Hepatocellular Carcinoma
, 2013; 13(3): 300 - 312Jordi Muntane, Angel J. De la Rosa, Fernando Docobo, Rocio Garcia-Carbonero and Francisco J. Padillo
Novel Approaches for Molecular Targeted Therapy of Breast Cancer: Interfering with PI3K/AKT/mTOR Signaling
, 2013; 13(2): 188 - 204Thomas W. Grunt and Gabriella L. Mariani
Current Status and Future Perspectives of PI3K and mTOR Inhibitor as Anticancer Drugs in Breast Cancer
, 2013; 13(2): 175 - 187Xiaobei Zhang, Xi-ru Li and Jin Zhang
Cancer Stem Cell as a Potential Therapeutic Target in Hepatocellular Carcinoma
, 2012; 12(9): 1081 - 1094Roberta W.C. Pang and Ronnie T.P. Poon
Scope of Nanotechnology-based Radiation Therapy and Thermotherapy Methods in Cancer Treatment
, 2012; 12(8): 998 - 1015Mohamadreza K. Bakht, Mahdi Sadeghi, Milad Pourbaghi-Masouleh and Claudio Tenreiro
Membrane Transporters as Determinants of the Pharmacology of Platinum Anticancer Drugs
, 2012; 12(8): 962 - 986Johnson J. Liu, Jun Lu and Mark J. McKeage
A Comprehensive Overview of Targeted Therapy in Metastatic Renal Cell Carcinoma
, 2012; 12(7): 857 - 872Z. Mihaly, Z. Sztupinszki, P. Surowiak and B. Gyorffy
Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma
, 2012; 12(7): 838 - 846P. Tagliaferri, M. Rossi, M. T. Di Martino, N. Amodio, E. Leone, A. Gulla, A. Neri and P. Tassone
MicroRNAs in the Pathobiology of Multiple Myeloma
, 2012; 12(7): 823 - 837Marta Lionetti, Luca Agnelli, Luigia Lombardi, Pierfrancesco Tassone and Antonino Neri
Mouse Models as a Translational Platform for the Development of New Therapeutic Agents in Multiple Myeloma
, 2012; 12(7): 814 - 822P. Tassone, P. Neri, R. Burger, M. T. Di Martino, E. Leone, N. Amodio, M. Caraglia and P. Tagliaferri
Molecular Targets for the Treatment of Multiple Myeloma
, 2012; 12(7): 757 - 767Marco Rossi, Maria Teresa Di Martino, Eugenio Morelli, Marzia Leotta, Antonietta Rizzo, Anna Grimaldi, Gabriella Misso, Pierfrancesco Tassone and Michele Caraglia
Emerging Roles for Modulation of microRNA Signatures in Cancer Chemoprevention
, 2012; 12(6): 716 - 740K. Neelakandan, P. Babu and S. Nair
High CXCR4 Expression Correlates with Sunitinib Poor Response in Metastatic Renal Cancer
, 2012; 12(6): 693 - 702C. D'Alterio, L. Portella, A. Ottaiano, M. Rizzo, G. Carteni, S. Pignata, G. Facchini, S. Perdona, G. Di Lorenzo, R. Autorino, R. Franco, A. La Mura, O. Nappi, G. Castello and S. Scala
Two Novel GPER Agonists Induce Gene Expression Changes and Growth Effects in Cancer Cells
, 2012; 12(5): 531 - 542R. Lappano, C. Rosano, M. F. Santolla, M. Pupo, E. M. De Francesco, P. De Marco, M. Ponassi, A. Spallarossa, A. Ranise and M. Maggiolini
An Epigenetic Approach to Pancreatic Cancer Treatment: The Prospective Role of Histone Deacetylase Inhibitors
, 2012; 12(4): 439 - 452Nicola Tinari, Michele De Tursi, Antonino Grassadonia, Marinella Zilli, Liborio Stuppia, Stefano Iacobelli and Clara Natoli
Genetic Variants in Genes Involved in Mechanisms of Chemoresistance to Anticancer Drugs
, 2012; 12(4): 402 - 438J. J.G. Marin, O. Briz, M. J. Monte, A. G. Blazquez and R. I.R. Macias
Targeting EGFR for Treatment of Glioblastoma: Molecular Basis to Overcome Resistance
, 2012; 12(3): 197 - 209T. E. Taylor, F. B. Furnari and W. K. Cavenee
Nanotech Revolution for the Anti-Cancer Drug Delivery through Blood- Brain-Barrier
, 2012; 12(3): 186 - 196M. Caraglia, G. De Rosa, G. Salzano, D. Santini, M. Lamberti, P. Sperlongano, A. Lombardi, A. Abbruzzese and R. Addeo
Anticancer Drugs Aimed at E6 and E7 Activity in HPV-Positive Cervical Cancer
, 2012; 12(2): 170 - 184S. Tan, E. G.E. de Vries, A. G.J. van der Zee and S. de Jong
Adding to the Mix: Fibroblast Growth Factor and Platelet-Derived Growth Factor Receptor Pathways as Targets in Non – small Cell Lung Cancer
, 2012; 12(2): 107 - 123S. A. Kono, L. E. Heasley, R. C. Doebele and D. R. Camidge
Targeting ATP7A to Increase the Sensitivity of Neuroblastoma Cells to Retinoid Therapy
, 2011; 11(7): 826 - 836B. B. Cheung and G. M. Marshall
Strategies for Overcoming Inherent and Acquired Resistance to EGFR Inhibitors by Targeting Downstream Effectors in the RAS/PI3K Pathway
, 2010; 10(8): 824 - 833A. J. Weickhardt, N. C. Tebbutt and J. M. Mariadason
Dexamethasone Synergizes with Lenalidomide to Inhibit Multiple Myeloma Tumor Growth, But Reduces Lenalidomide-Induced Immunomodulation of T and NK Cell Function
, 2010; 10(2): 155 - 167A. K. Gandhi, J. Kang, L. Capone, A. Parton, L. Wu, L. H. Zhang, D. Mendy, A. Lopez-Girona, T. Tran, L. Sapinoso, W. Fang, S. Xu, G. Hampton, J. B. Bartlett and P. Schafer
Potential Uses of MicroRNA in Lung Cancer Diagnosis, Prognosis, and Therapy
, 2009; 9(4): 572 - 594Qi Zhao Wang, William Xu, Nagy Habib and Ruian Xu
S100A8 and S100A9 Overexpression Is Associated with Poor Pathological Parameters in Invasive Ductal Carcinoma of the Breast
, 2008; 8(4): 243 - 252Kazumori Arai, Sachiko Takano, Takumi Teratani, Yasuhiro Ito, Toshihiro Yamada and Ryushi Nozawa
Ribonucleotide Reductase Inhibitors and Future Drug Design
, 2006; 6(5): 409 - 431J. Shao, B. Zhou, Bernard Chu and Y. Yen
Liposomal Muramyl Tripeptide Phosphatidylethanolamine: Targeting and Activating Macrophages for Adjuvant Treatment of Osteosarcoma
, 2006; 6(2): 123 - 133A. Nardin, M. L. Lefebvre, K. Labroquere, O. Faure and J. P. Abastado
Editor-in-Chief
Ruiwen Zhang
Center for Drug Discovery
University of Houston
3455 Cullen Blvd.
Houston, TX 77204
(USA)
Center for Drug Discovery
University of Houston
3455 Cullen Blvd.
Houston, TX 77204
COPE Compliant
About the Journal
For Authors
For Librarians & Readers
Quick Links
Journal History
Current Cancer Drug Targets was launched in 2001. Dr. Ruiwen Zhang serves as the Editor-in-Chief of the journal.
Advertisement
Webmaster Contact: info@benthamscience.net